POS0712 “EXTRA”- CRITERIA ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUS (PRELIMINARY DATA)

Background: The study of antiphospholipid antibodies (aPL), not included in the Sydney diagnostic criteria, syndrome (APS) and systemic lupus erythematosus (SLE) is poorly understood. Objectives: To determine frequency detection IgA-aCL IgA-aβ2GP1 IgG to β2GP1 domain 1 (IgG-aβ2GP1-D1) patients with APS without SLE. Methods: ELISA chemiluminescence assays (CMA) were used test 63 sera patients: 22 (35%) primary (pAPS) 41 (65%) SLE (secondary (sAPS)), mean age 38,0 [33,0 – 43,0] years disease duration 4,0 [0,1 9,9]. Both methods IgG/IgM-aCL IgG/IgM-aβ2GP1. CMA was for research IgG/IgM/IgA-aCL, IgG/IgM/IgA-aβ2GPI IgG-aβ2GP1-D1. Of them 49 (78%) (18 pAPS; 31 sAPS) displayed major thrombotic events 18 pregnant women had pregnancy morbidity past history. Lupus anticoagulant (LA) positivity 9 out 12 who it determined. LA investigated due therapy remaining 52 patients. Results: IgG/IgM-aß2GP1 recorded 44/18 50/17 by 55/19 59/16 CMA, respectively. found 35 (56%) Thirty IgA-positive positive IgG-aCL ELISA: highly positive, 6 medium 2 low IgM-aCL detected 13 (37%) 11 positive. combined 34 16 CMA. IgG-aß2GP1 32 (24 –highly 5 3 positive) IgM-aß2GP1 IgA-aß2GP1 same both (in patients). 30 (48%) They all cases methods. 14 IgA-aß2GP1, combination 27 most 20) 10 (highly - 8). 28 (high 21) –7). IgG-aß2GP1-D1 revealed 48 (76%) It 38, 15 ELISA. as follows: 46, 17, 33 In cases, IgG-aß2gp1-D1 aCL levels. associated 42 47 IgМ-aβ2GP1 respectively, 29. Isolated observed. Conclusion: 56% (35 63), 48% (30 IgG-aβ2GP1-D1 76% (48 63). There isolated this “extra” criterial antibodies. presence IgA-aCL, IgA-aβ2GP1, IgG/IgM- aβ2GP1. Disclosure Interests: None declared